Muscular Disorders, Atrophic clinical trials at University of California Health
2 in progress, 0 open to eligible people
A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy (HOPE-3)
Sorry, not yet accepting patients
HOPE-3 is a multi-center, randomized, double-blind, placebo-controlled clinical trial evaluating the safety and efficacy of a cell therapy called CAP-1002 in study participants with Duchenne muscular dystrophy (DMD). Non-ambulatory and ambulatory boys and young men who meet eligibility criteria will be randomly assigned to receive either CAP-1002 or placebo every 3 months for a total of 4 doses during a 12-month period.
at UC Davis
Long-Term Outcomes of Ataluren in Duchenne Muscular Dystrophy
Sorry, in progress, not accepting new patients
This study is a long-term study of ataluren in participants with nonsense mutation Duchenne muscular dystrophy.
at UC Davis UCSF
Our lead scientists for Muscular Disorders, Atrophic research studies include Craig McDonald, MD.
Last updated: